1. Academic Validation
  2. Novel piperidinylpyrimidine derivatives as inhibitors of HIV-1 LTR activation

Novel piperidinylpyrimidine derivatives as inhibitors of HIV-1 LTR activation

  • Bioorg Med Chem. 2008 Nov 15;16(22):9804-16. doi: 10.1016/j.bmc.2008.09.059.
Norio Fujiwara 1 Takashi Nakajima Yutaka Ueda Hitoshi Fujita Hajime Kawakami
Affiliations

Affiliation

  • 1 Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd, Enoki 33-94, Suita, Osaka 564-0053, Japan. norio-fujiwara@ds-pharma.co.jp
Abstract

Piperidinylpyrimidine derivatives, previously prepared as inhibitors of TNF-alpha production, were evaluated for their inhibitory activity against HIV-1 LTR activation. Some of these derivatives inhibited activation of HIV-1 LTR-directed CAT gene expression induced by PMA in Jurkat cells. In this report, we describe SAR in this series of compounds and show that the 3,4-methylenedioxybenzoyl (piperonyloyl) group on the nitrogen of piperidine and lipophilic substitution at the C(6)-position of pyrimidine are important for this inhibitory activity. Some of the synthesized compounds also inhibited HIV-1 LTR transactivation induced by viral protein Tat. These results suggest that piperidinylpyrimidines are useful as potent AIDS therapeutics that directly inhibit HIV-1 LTR activation and indirectly suppress TNF-alpha production.

Figures